The Science Marketer 🧬 Helping science marketing & communication professionals get inspired
This week in the world of #biotech #fundraising : 🇺🇸 Korro Bio, Inc. | $117 million PIPE | RNA editing | clinical in alpha-1 antitrypsin deficiency (AATD) 🇺🇸 LEXEO Therapeutics | $100 million IPO | gene therapies | phase 1/2 in cardiac Friedreich’s ataxia and Alzheimer’s disease 🇺🇸 Gate Bioscience | $60 million series A | molecular gates | drug discovery stage 🇺🇸 Imagine Pharma | $32.5 million series A | therapeutic and regenerative medicine | phase 1 for anemia in patients with renal failure, undergoing chemotherapy and other causes 🇨🇭 Memo Therapeutics AG | CHF 25 million ($27.76 million) series C | antibody-based therapies | phase 2/3 in BK virus infection in kidney transplant recipients 🇺🇸 ProJenX | $15 million series A | brain-penetrant kinase inhibitors | clinical in amyotrophic lateral sclerosis (ALS) 🇧🇪 Amyl Therapeutics | €5 million ($5.35 million) series A extension | amyloid-targeting therapies | preclinical in amyloid light chain (AL) amyloidosis 💡My take on it: We haven't seen an IPO in a while, but since Lexeo's didn't go particularly well (stock fell 15% in trading debut), we may see even more companies shying away from the public market.
